Subscribe to RSS
DOI: 10.1055/s-0036-1578672
Investigation Of Optimal Growth Soil Conditions For Pinellia Triparita (Blume) Schott By Enlargement And Propagation Comparative Study
Pinellia tripartita (Blume) Schott is an herbaceous perennial plant belonging to the Araceae family. It is larger than Pinellia ternata (Thunb.) Makino which is included in Korean Pharmacopoeia (KP), while P. tripartita is not [1]. The enlargement and propagation study of P. ternate has not been reported and it would be required to study the fundamental experimental design of P. ternata using P. triparita. In this study, we compared the tuber growth in different combinations of mixed soils using six compositions. Tubers used in the study were cultured in vitro and divided into two groups. Type I was composed of plants with a diameter of more than 1 cm and group II contained plants with a diameter less than 1 cm. Enlargement and propagation of tubers were determined by measuring the plant height, number of fresh leaves, dead leaves, number of bullets, tuber size, and fresh/dry weight. The size/weight and numbers of tubers from the mixed soil B (cocopeat 68%, peat moss 14.7%, vermiculite 3.0%, perlite 7.0% and zeolite 7.0%) produced the best growth for eight weeks. In case of Type I, GI (Growth index) of tuber size and weight were 45% and 101%, respectively. The difference of growth was doubled compared to the poor growth treatments. These results could be used as basic information for the experimental design for the P. ternata. In addition, the study of the physical and chemical properties by mixed soils will be required future study.
Acknowledgement: This work was supported by the Establishment of Molecular Authentication System and Development of Seedling Proliferation Techniques for the Production of Authentic Herbal Medicines (K15421), the Korea Institute of Oriental Medicine (KIOM) to the Ministry of Science, ICT & Future Planning (MSIP), and Republic of Korea.
Reference: [1] The Korean Pharmacopoeia 10th edition. The KFDA Notification No. 2012 – 129. 2012. Dec 27th. Korea Food & Drug Administration.